NCT05739110|Completed
HCC Staging Modified by Tumor Micronecrosis
Optimizing Hepatocellular Carcinoma Disease Staging Systems by Incorporating Tumor Micronecrosis: A Multi-institutional Retrospective Study
Loading search results
Optimizing Hepatocellular Carcinoma Disease Staging Systems by Incorporating Tumor Micronecrosis: A Multi-institutional Retrospective Study
Sponsor study identifier
observational
1,100
1 country
2
Study Start
July 15, 2022
Actual (reported)Primary Completion
December 1, 2022
Actual (reported)Study Completion
January 15, 2023
Actual (reported)Tumor micronecrosis is a pathological feature that reflects malignant biological behavior in hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic significance of tumor micronecrosis based on the current BCLC and TNM staging systems, and futher improve the performance of the staging models by establishing modified new staging models including tumor micronecrosis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 15, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 15, 2022
Actual (reported)December 1, 2022
Actual (reported)January 15, 2023
Actual (reported)February 11, 2023
Actual (reported)February 22, 2023
Actual (reported)Overall survival
the number of months from the date of surgery to the date of the last follow-up visit or time of death.
from date after liver resection until death or last follow-up, whichever came first, assessed up to 72 months
Disease-free survival
from date after liver resection until recurrence or last follow-up, whichever came first, assessed up to 72 months
Hepatocellular patients with tumor micronecrosis.
Hepatocellular patients without tumor micronecrosis.
whether HCC patients have tumor micronecrosis or not
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
This retrospective study enrolled patients who underwent liver resection from four institutions in China: the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU) (n = 896), Mengchao Hepatobiliary Hospital of Fujian Medical University (n = 94), the Second Affiliated Hospital of Nanchang University (n = 84), and Huzhou Central Hospital (n = 36).
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310009, China
1,100 participants (actual enrollment reported by the registry).
First Submitted
February 11, 2023
First Posted
February 22, 2023
Study Start
July 15, 2022
Actual (reported)SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma
Contact the study team to confirm eligibility.
Primary Completion
December 1, 2022
Actual (reported)Study Completion
January 15, 2023
Actual (reported)Last Updated
February 22, 2023
Record last verified: 2023-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: